{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:39:43Z","timestamp":1772156383890,"version":"3.50.1"},"posted":{"date-parts":[[2023,12,18]]},"group-title":"Biochemistry","reference-count":68,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,10,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Inhibition of Bruton\u2019s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders and multiple sclerosis. Since the approval of the first BTK inhibitor (BTKi), Ibrutinib, several other inhibitors including Acalabrutinib, Zanubrutinib, Tirabrutinib and Pirtobrutinib have been clinically approved. All are covalent active site inhibitors, with the exception of the reversible active site inhibitor Pirtobrutinib. The large number of available inhibitors for the BTK target creates challenges in choosing the most appropriate BTKi for treatment. Side-by-side comparisons in CLL have shown that different inhibitors may differ in their treatment efficacy. Moreover, the nature of the resistance mutations that arise in patients appears to depend on the specific BTKi administered. We have previously shown that Ibrutinib binding to the kinase active site causes unanticipated long-range effects on the global conformation of BTK (Joseph, R.E., et al., 2020,\n                  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.7554\/eLife.60470\">https:\/\/doi.org\/10.7554\/eLife.60470<\/jats:ext-link>\n                  ). Here we show that binding of each of the five approved BTKi to the kinase active site brings about distinct allosteric changes that alter the conformational equilibrium of full-length BTK. Additionally, we provide an explanation for the resistance mutation bias observed in CLL patients treated with different BTKi and characterize the mechanism of action of two common resistance mutations: BTK T474I and L528W.\n                <\/jats:p>","DOI":"10.1101\/2023.12.18.572223","type":"posted-content","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T22:35:29Z","timestamp":1702938929000},"source":"Crossref","is-referenced-by-count":2,"title":["Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia"],"prefix":"10.64898","author":[{"given":"Raji E.","family":"Joseph","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6133-5689","authenticated-orcid":false,"given":"Thomas E.","family":"Wales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-9782","authenticated-orcid":false,"given":"Sandrine","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8813-1635","authenticated-orcid":false,"given":"Robert G.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Bruce","family":"Fulton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6918-9476","authenticated-orcid":false,"given":"John R.","family":"Engen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5033-2236","authenticated-orcid":false,"given":"Martin J. S.","family":"Dyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-7244","authenticated-orcid":false,"given":"Amy H.","family":"Andreotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024101402300700000_2023.12.18.572223v2.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"2024101402300700000_2023.12.18.572223v2.2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.51"},{"key":"2024101402300700000_2023.12.18.572223v2.3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"2024101402300700000_2023.12.18.572223v2.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"2024101402300700000_2023.12.18.572223v2.5","doi-asserted-by":"crossref","unstructured":"Rozkiewicz, D. , et al., Bruton\u2019s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials. Molecules, 2023. 28(5).","DOI":"10.3390\/molecules28052400"},{"issue":"1","key":"2024101402300700000_2023.12.18.572223v2.6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features","volume":"17","year":"2022","journal-title":"Target Oncol"},{"key":"2024101402300700000_2023.12.18.572223v2.7","doi-asserted-by":"crossref","unstructured":"Montoya, S. and M.C. Thompson , Non-Covalent Bruton\u2019s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia. Cancers (Basel), 2023. 15(14).","DOI":"10.3390\/cancers15143648"},{"key":"2024101402300700000_2023.12.18.572223v2.8","doi-asserted-by":"crossref","first-page":"655489","DOI":"10.3389\/fcell.2021.655489","article-title":"Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK","volume":"9","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2024101402300700000_2023.12.18.572223v2.9","doi-asserted-by":"crossref","unstructured":"Frustaci, A.M. , et al., Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities. Cancers (Basel), 2023. 15(5).","DOI":"10.3390\/cancers15051504"},{"issue":"8","key":"2024101402300700000_2023.12.18.572223v2.10","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/all.15261","article-title":"Bruton\u2019s tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions","volume":"77","year":"2022","journal-title":"Allergy"},{"key":"2024101402300700000_2023.12.18.572223v2.11","doi-asserted-by":"crossref","unstructured":"Robak, E. and T. Robak , Bruton\u2019s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. J Clin Med, 2022. 11(10).","DOI":"10.3390\/jcm11102807"},{"issue":"31","key":"2024101402300700000_2023.12.18.572223v2.12","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024101402300700000_2023.12.18.572223v2.13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2211582"},{"key":"2024101402300700000_2023.12.18.572223v2.14","doi-asserted-by":"crossref","first-page":"20406207221116577","DOI":"10.1177\/20406207221116577","article-title":"Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations","volume":"13","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"2024101402300700000_2023.12.18.572223v2.15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41375-022-01732-9","article-title":"Managing Waldenstrom\u2019s macroglobulinemia with BTK inhibitors","volume":"37","year":"2023","journal-title":"Leukemia"},{"key":"2024101402300700000_2023.12.18.572223v2.16","doi-asserted-by":"crossref","unstructured":"Joseph, R.E. , et al., Differential impact of BTK active site inhibitors on the conformational state of full-length BTK. Elife, 2020. 9.","DOI":"10.7554\/eLife.60470"},{"key":"2024101402300700000_2023.12.18.572223v2.17","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.7b12430"},{"key":"2024101402300700000_2023.12.18.572223v2.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02240-6"},{"key":"2024101402300700000_2023.12.18.572223v2.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314712110"},{"key":"2024101402300700000_2023.12.18.572223v2.20","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3389\/fonc.2020.00894","article-title":"Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents","volume":"10","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"2024101402300700000_2023.12.18.572223v2.21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia","volume":"1","year":"2015","journal-title":"JAMA Oncol"},{"key":"2024101402300700000_2023.12.18.572223v2.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-719294"},{"key":"2024101402300700000_2023.12.18.572223v2.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"issue":"20","key":"2024101402300700000_2023.12.18.572223v2.24","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","year":"2022","journal-title":"Blood Adv"},{"key":"2024101402300700000_2023.12.18.572223v2.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1402716"},{"issue":"8","key":"2024101402300700000_2023.12.18.572223v2.26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of Resistance to Noncovalent Bruton\u2019s Tyrosine Kinase Inhibitors","volume":"386","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"2024101402300700000_2023.12.18.572223v2.27","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2022009366","article-title":"BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib","volume":"7","year":"2023","journal-title":"Blood Adv"},{"key":"2024101402300700000_2023.12.18.572223v2.28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2019-125488","article-title":"BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib","volume":"134","year":"2019","journal-title":"Blood"},{"key":"2024101402300700000_2023.12.18.572223v2.29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations","volume":"134","year":"2019","journal-title":"Blood"},{"key":"2024101402300700000_2023.12.18.572223v2.30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282"},{"key":"2024101402300700000_2023.12.18.572223v2.31","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18418"},{"issue":"4","key":"2024101402300700000_2023.12.18.572223v2.32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.31831","article-title":"Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation","volume":"125","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"2024101402300700000_2023.12.18.572223v2.33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ijc.32502","article-title":"Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib","volume":"146","year":"2020","journal-title":"Int J Cancer"},{"issue":"42","key":"2024101402300700000_2023.12.18.572223v2.34","doi-asserted-by":"crossref","first-page":"68833","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"2024101402300700000_2023.12.18.572223v2.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2012.10.023"},{"issue":"8","key":"2024101402300700000_2023.12.18.572223v2.36","doi-asserted-by":"crossref","first-page":"e0290872","DOI":"10.1371\/journal.pone.0290872","article-title":"Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib","volume":"18","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"2024101402300700000_2023.12.18.572223v2.37","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","year":"2023","journal-title":"Blood"},{"issue":"17","key":"2024101402300700000_2023.12.18.572223v2.38","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton\u2019s Tyrosine Kinase","volume":"62","year":"2019","journal-title":"J Med Chem"},{"key":"2024101402300700000_2023.12.18.572223v2.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2017.07.014"},{"key":"2024101402300700000_2023.12.18.572223v2.40","doi-asserted-by":"crossref","unstructured":"Lin, D.Y. , Kueffer, L.E. , Juneja, P. , Wales, T. , et al., Conformational heterogeneity of the BTK PHTH domain drives multiple regulatory states. eLife, 2023.","DOI":"10.7554\/eLife.89489.1"},{"key":"2024101402300700000_2023.12.18.572223v2.41","doi-asserted-by":"crossref","unstructured":"Wang, Q. , et al., Autoinhibition of Bruton\u2019s tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate. Elife, 2015. 4.","DOI":"10.7554\/eLife.06074"},{"issue":"10","key":"2024101402300700000_2023.12.18.572223v2.42","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acschembio.6b00480","article-title":"Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations","volume":"11","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"11","key":"2024101402300700000_2023.12.18.572223v2.43","doi-asserted-by":"crossref","first-page":"102555","DOI":"10.1016\/j.jbc.2022.102555","article-title":"BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma","volume":"298","year":"2022","journal-title":"J Biol Chem"},{"issue":"736","key":"2024101402300700000_2023.12.18.572223v2.44","doi-asserted-by":"crossref","first-page":"eabg5216","DOI":"10.1126\/scisignal.abg5216","article-title":"Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK","volume":"15","year":"2022","journal-title":"Sci Signal"},{"key":"2024101402300700000_2023.12.18.572223v2.45","doi-asserted-by":"publisher","DOI":"10.1038\/385650a0"},{"key":"2024101402300700000_2023.12.18.572223v2.46","doi-asserted-by":"crossref","first-page":"949139","DOI":"10.3389\/fonc.2022.949139","article-title":"Editorial: Altered Expression of Proteins in Cancer: Function and Potential Therapeutic Targets","volume":"12","year":"2022","journal-title":"Front Oncol"},{"key":"2024101402300700000_2023.12.18.572223v2.47","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0804-2"},{"key":"2024101402300700000_2023.12.18.572223v2.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00195-4"},{"key":"2024101402300700000_2023.12.18.572223v2.49","doi-asserted-by":"publisher","DOI":"10.1124\/mol.116.107037"},{"key":"2024101402300700000_2023.12.18.572223v2.50","doi-asserted-by":"crossref","unstructured":"Li, W. , et al., Bruton\u2019s Tyrosine Kinase Inhibitors With Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling. Mol Cancer Ther, 2023.","DOI":"10.1158\/1535-7163.MCT-22-0642"},{"key":"2024101402300700000_2023.12.18.572223v2.51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-695098"},{"key":"2024101402300700000_2023.12.18.572223v2.52","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003423"},{"key":"2024101402300700000_2023.12.18.572223v2.53","doi-asserted-by":"crossref","first-page":"689472","DOI":"10.3389\/fimmu.2021.689472","article-title":"Resistance Mutations to BTK Inhibitors Originate From the NF-kappaB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway","volume":"12","year":"2021","journal-title":"Front Immunol"},{"key":"2024101402300700000_2023.12.18.572223v2.54","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.3390\/genes14122182","article-title":"Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)","volume":"14","year":"2023","journal-title":"Genes"},{"issue":"5","key":"2024101402300700000_2023.12.18.572223v2.55","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-022-00675-9","article-title":"Pirtobrutinib inhibits wild-type and mutant Bruton\u2019s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia","volume":"12","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"2024101402300700000_2023.12.18.572223v2.56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-022-00720-7","article-title":"Determining drug dose in the era of targeted therapies: playing it (un)safe?","volume":"12","year":"2022","journal-title":"Blood Cancer J"},{"key":"2024101402300700000_2023.12.18.572223v2.57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1803662115"},{"issue":"4","key":"2024101402300700000_2023.12.18.572223v2.58","doi-asserted-by":"crossref","first-page":"IJH31","DOI":"10.2217\/ijh-2020-0010","article-title":"Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia","volume":"9","year":"2020","journal-title":"Int J Hematol Oncol"},{"key":"2024101402300700000_2023.12.18.572223v2.59","doi-asserted-by":"publisher","DOI":"10.1021\/bi700127c"},{"key":"2024101402300700000_2023.12.18.572223v2.60","doi-asserted-by":"publisher","DOI":"10.1007\/BF00404272"},{"key":"2024101402300700000_2023.12.18.572223v2.61","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0459-y"},{"key":"2024101402300700000_2023.12.18.572223v2.62","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw880"},{"key":"2024101402300700000_2023.12.18.572223v2.63","doi-asserted-by":"publisher","DOI":"10.1002\/mas.20064"},{"key":"2024101402300700000_2023.12.18.572223v2.64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"2024101402300700000_2023.12.18.572223v2.65","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.084459"},{"key":"2024101402300700000_2023.12.18.572223v2.66","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"2024101402300700000_2023.12.18.572223v2.67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-664086"},{"key":"2024101402300700000_2023.12.18.572223v2.68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.12.18.572223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:41:10Z","timestamp":1768455670000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.12.18.572223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":68,"URL":"https:\/\/doi.org\/10.1101\/2023.12.18.572223","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.7554\/elife.95488.3","asserted-by":"subject"},{"id-type":"doi","id":"10.7554\/eLife.95488.3","asserted-by":"object"}],"has-version":[{"id-type":"doi","id":"10.7554\/eLife.95488.1","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.95488.2","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2023,12,18]]},"subtype":"preprint"}}